Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Plos One|August 13, 2021
Are neighbourhoods of tuberculosis cases a high-risk population for active intervention? A protocol for tuberculosis active case findingBachti Alisjahbana, Raspati Cundarani Koesoemadinata, Panji Fortuna Hadisoemarto, et al.
Leukemia & Lymphoma|July 21, 2012
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapseChun Yew Fong, George Grigoriadis, Jay Hocking, et al.
American Heart Journal|March 30, 2006
A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is plannedKunadian Vijayalakshmi, Victoria J Whittaker, Andrew Sutton, et al.
Scientific Reports|September 21, 2019
Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphomaSumita Ratnasingam, Joshua Casan, Jake Shortt, et al.
Bone Marrow Transplantation|March 11, 2018
Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myelomaChong Chyn Chua, Hui Yin Lim, Khai Li Chai, et al.
American Journal of Hematology|February 6, 2015
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefitSimon J Harrison, Hang Quach, Emma Link, et al.
Science Advances|May 14, 2025
The role of dopaminergic medication and specific pathway alterations in idiopathic and <i>PRKN/PINK1</i>-mediated Parkinson's diseaseAlexander Balck, Max Borsche, Philip Campbell, et al.
Journal of Telemedicine and Telecare|December 9, 2022
Telehealth in cancer care during the COVID-19 pandemicKate Burbury, Peter Brooks, Leslie Gilham, et al.
Annals of Neurology|March 28, 2024
α-Synuclein Pathology in PRKN-Linked Parkinson's Disease: New Insights from a Blood-Based Seed Amplification AssayAnnika Kluge, Max Borsche, Linn Streubel-Gallasch, et al.
Hemasphere|November 18, 2022
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial ResultsPaolo Ghia, Andrzej Pluta, Małgorzata Wach, et al.
Pageof 6